LOGiC - Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus Lapatinib

NCT00680901 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

545

Enrollment

INDUSTRY

Sponsor class

Conditions

Neoplasms, Gastrointestinal Tract

Interventions

DRUG: Lapatinib
DRUG: Placebo
DRUG: Capecitabine
DRUG: Oxaliplatin

Sponsor

Novartis Pharmaceuticals